← All trials
NCT03195010
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 9, 2017
- Primary completion
- Oct 5, 2018
- Completion date
- Oct 5, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of WashingtonLead sponsor
- University of WashingtonOverall official - principal investigator
- National Cancer Institute (NCI)Collaborator
Drugs studied
Indications studied
- Lymphoma, Non-Hodgkin
- Myelodysplastic Syndromes
- Thrombocytopenia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Biphenotypic, Acute
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Acute
- Hematopoietic Stem Cell Transplantation
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Venous Thromboembolism
- Primary Myelofibrosis
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.